DE69334197D1 - Helicobacter pylori Cytotoxin verwendbar in Impfstoffe und Diagnostik - Google Patents

Helicobacter pylori Cytotoxin verwendbar in Impfstoffe und Diagnostik

Info

Publication number
DE69334197D1
DE69334197D1 DE69334197T DE69334197T DE69334197D1 DE 69334197 D1 DE69334197 D1 DE 69334197D1 DE 69334197 T DE69334197 T DE 69334197T DE 69334197 T DE69334197 T DE 69334197T DE 69334197 D1 DE69334197 D1 DE 69334197D1
Authority
DE
Germany
Prior art keywords
vaccines
diagnostics
useful
helicobacter pylori
pylori cytotoxin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69334197T
Other languages
English (en)
Other versions
DE69334197T2 (de
Inventor
Antonello Covacci
Massimo Bugnoli
John Telford
Giovanni Macchia
Rino Rappuoli
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GSK Vaccines SRL
Original Assignee
Novartis Vaccines and Diagnostics SRL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from ITFI920052A external-priority patent/IT1262895B/it
Application filed by Novartis Vaccines and Diagnostics SRL filed Critical Novartis Vaccines and Diagnostics SRL
Application granted granted Critical
Publication of DE69334197D1 publication Critical patent/DE69334197D1/de
Publication of DE69334197T2 publication Critical patent/DE69334197T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/205—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Campylobacter (G)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6888—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms
    • C12Q1/689—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/35—Fusion polypeptide containing a fusion for enhanced stability/folding during expression, e.g. fusions with chaperones or thioredoxin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/975—Kit
DE69334197T 1992-03-02 1993-03-02 Helicobacter pylori Cytotoxin verwendbar in Impfstoffe und Diagnostik Expired - Lifetime DE69334197T2 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
ITFI920052 1992-03-02
ITFI920052A IT1262895B (it) 1992-03-02 1992-03-02 Proteina estratta da ceppi citotossici di helicobacter pylori, gene che la esprime, uso della proteina come vaccino o diagnostico.
EPPCT/EP93/00158 1993-01-25
WOPCT/EP93/00158 1993-01-25

Publications (2)

Publication Number Publication Date
DE69334197D1 true DE69334197D1 (de) 2008-02-14
DE69334197T2 DE69334197T2 (de) 2008-12-11

Family

ID=26069992

Family Applications (2)

Application Number Title Priority Date Filing Date
DE69334197T Expired - Lifetime DE69334197T2 (de) 1992-03-02 1993-03-02 Helicobacter pylori Cytotoxin verwendbar in Impfstoffe und Diagnostik
DE69333110T Expired - Lifetime DE69333110T2 (de) 1992-03-02 1993-03-02 Mit dem cytotoxin von helicobacter pylori assoziiertes, immunodominantes antigen verwendbar in impfstoffen und zur diagnose

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE69333110T Expired - Lifetime DE69333110T2 (de) 1992-03-02 1993-03-02 Mit dem cytotoxin von helicobacter pylori assoziiertes, immunodominantes antigen verwendbar in impfstoffen und zur diagnose

Country Status (7)

Country Link
US (3) US6077706A (de)
EP (1) EP0967279B1 (de)
JP (4) JP3368902B2 (de)
AU (1) AU3630093A (de)
CA (2) CA2383007A1 (de)
DE (2) DE69334197T2 (de)
WO (1) WO1993018150A1 (de)

Families Citing this family (92)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5866375A (en) * 1991-10-31 1999-02-02 Chiron S.P.A. Method for the culture of microorganisms of the genera helicobacter, campylobacter and arcobacter employing culture media comprising cyclodextrins
EP0629132B1 (de) * 1992-02-26 2004-08-11 Vanderbilt University Gereinigtes vakuolisierendes toxin aus helicobacter pylori und methoden zu dessen verwendung
US5721349A (en) * 1992-02-26 1998-02-24 Vanderbilt University Vacuolating toxin-deficient H. pylori
US5928865A (en) * 1992-03-02 1999-07-27 Chiron S.P.A. Compositions comprising isolated Helicobacter pylori CagI polynucleotides and method of preparation thereof
IT1262896B (it) * 1992-03-06 1996-07-22 Composti coniugati formati da proteine heat shock (hsp) e oligo-poli- saccaridi, loro uso per la produzione di vaccini.
MX9301706A (es) * 1992-04-13 1994-05-31 Oravax Inc Composicion de vacuna para el tratamiento de la infeccion por helicobacter.
US5403924A (en) * 1992-10-13 1995-04-04 Vanderbilt University Taga gene and methods for detecting predisposition to peptic ulceration
US5733740A (en) * 1992-10-13 1998-03-31 Vanderbilt University Taga gene and methods for detecting predisposition to peptic ulceration and gastric carcinoma
US6290962B1 (en) * 1992-11-03 2001-09-18 Oravax, Inc. Urease-based vaccine and treatment for helicobacter infection
US5972336A (en) * 1992-11-03 1999-10-26 Oravax Merieux Co. Urease-based vaccine against helicobacter infection
US6258359B1 (en) 1993-05-19 2001-07-10 Institut Pasteur Immunogenic compositions against helicobacter infection, polypeptides for use in the compositions, and nucleic acid sequences encoding said polypeptides
WO1995014093A1 (en) * 1993-05-19 1995-05-26 Institut Pasteur Immunogenic compositions against helicobacter infection, polypeptides for use in the compositions and nucleic acid sequences encoding said polypeptides
GB9313279D0 (en) * 1993-06-28 1993-08-11 Medical Res Council Protection against infection with helicobacter pylori
US6406703B1 (en) 1993-07-27 2002-06-18 Csl Limited Treatment of H. pylori associated gastroduodenal disease
WO1995003824A1 (en) * 1993-07-27 1995-02-09 Csl Limited Treatment of h. pylori associated gastroduodenal disease
US5750119A (en) * 1994-01-13 1998-05-12 Mount Sinai School Of Medicine Of The City University Of New York Immunotherapeutic stress protein-peptide complexes against cancer
US5997873A (en) * 1994-01-13 1999-12-07 Mount Sinai School Of Medicine Of The City University Of New York Method of preparation of heat shock protein 70-peptide complexes
US5961979A (en) * 1994-03-16 1999-10-05 Mount Sinai School Of Medicine Of The City University Of New York Stress protein-peptide complexes as prophylactic and therapeutic vaccines against intracellular pathogens
GB2290710B (en) * 1994-06-29 1998-03-25 Reckitt & Colmann Prod Ltd Protease from helicobacter pylori for use in vaccines/therapeutic compositions
ATE229978T1 (de) * 1994-07-01 2003-01-15 Chiron Corp Helicobacter proteine und impstoffe
GB9505438D0 (en) * 1995-03-17 1995-05-03 Sod Conseils Rech Applic Antisense oligonucleotides
WO1997003359A1 (en) * 1995-07-07 1997-01-30 Oravax, Inc. Helicobacter clpb
US5935576A (en) 1995-09-13 1999-08-10 Fordham University Compositions and methods for the treatment and prevention of neoplastic diseases using heat shock proteins complexed with exogenous antigens
US5837251A (en) * 1995-09-13 1998-11-17 Fordham University Compositions and methods using complexes of heat shock proteins and antigenic molecules for the treatment and prevention of neoplastic diseases
US5985270A (en) * 1995-09-13 1999-11-16 Fordham University Adoptive immunotherapy using macrophages sensitized with heat shock protein-epitope complexes
WO1997013784A1 (fr) * 1995-10-09 1997-04-17 Pasteur Merieux Serums Et Vaccins Recepteur lactoferrine d'helicobacter
AU1463097A (en) * 1996-01-04 1997-08-01 Rican Limited Helicobacter pylori bacterioferritin
JPH1033179A (ja) * 1996-07-24 1998-02-10 Fuso Yakuhin Kogyo Kk 感染症診断用プローブ
WO1998012562A1 (en) * 1996-09-20 1998-03-26 Cortecs International Limited Adhesins from heliobacter pylori and their diagnostic and therapeutic uses
PT946874E (pt) * 1996-12-19 2002-10-31 Chiron Corp Diagnostico de helicobacter pylori
US5830464A (en) * 1997-02-07 1998-11-03 Fordham University Compositions and methods for the treatment and growth inhibition of cancer using heat shock/stress protein-peptide complexes in combination with adoptive immunotherapy
US6017540A (en) 1997-02-07 2000-01-25 Fordham University Prevention and treatment of primary and metastatic neoplastic diseases and infectious diseases with heat shock/stress protein-peptide complexes
AU751433B2 (en) * 1997-04-30 2002-08-15 Merieux Oravax Anti-(helicobacter) vaccine composition for use by the subdiaphragmatic systemic route, and combined mucosal/parenteral immunization method
FR2748477B1 (fr) * 1997-07-01 2001-07-13 Pasteur Merieux Serums Vacc Nouvelle proteine membranaire d'helicobacter pylori
US6914131B1 (en) 1998-10-09 2005-07-05 Chiron S.R.L. Neisserial antigens
EP1042480A1 (de) * 1997-12-31 2000-10-11 Stressgen Biotechnologies Corporation Streptokokken-hitzeschock-proteine, mitglieder der hsp60-familie
US6585975B1 (en) * 1998-04-30 2003-07-01 Acambis, Inc. Use of Salmonella vectors for vaccination against helicobacter infection
JP4346821B2 (ja) * 1998-04-30 2009-10-21 カイロン ソチエタ ア レスポンサビリタ リミタータ Ｈ．Ｐｙｌｏｒｉによる感染に対する免疫化および処置
US6838553B1 (en) * 1999-10-05 2005-01-04 Academia Sinica Peptide repeat immunogens
GB9924060D0 (en) * 1999-10-11 1999-12-15 Chiron Spa VIP54 protein
EP2975127A1 (de) 1999-10-29 2016-01-20 GlaxoSmithKline Biologicals SA Neisseria antigenpeptide
EP2275129A3 (de) 2000-01-17 2013-11-06 Novartis Vaccines and Diagnostics S.r.l. Ergänzter Außenmembranvesikel-Impfstoff gegen Meningokokken
AU2001266694C1 (en) 2000-06-02 2005-09-01 University Of Connecticut Health Center Complexes of alpha (2) macroglobulin and antigenic molecules for immunotherapy
US20020107368A1 (en) * 2000-12-07 2002-08-08 Jing-Hui Tian Helicobacter proteins, gene sequences and uses thereof
EP2305299B1 (de) 2001-05-31 2017-03-01 GlaxoSmithKline Biologicals SA Chimäre alphavirus-replikonpartikel
GB0115176D0 (en) 2001-06-20 2001-08-15 Chiron Spa Capular polysaccharide solubilisation and combination vaccines
GB0118249D0 (en) 2001-07-26 2001-09-19 Chiron Spa Histidine vaccines
GB0121591D0 (en) 2001-09-06 2001-10-24 Chiron Spa Hybrid and tandem expression of neisserial proteins
JP4384489B2 (ja) 2001-08-20 2009-12-16 ユニバーシティー オブ コネティカット ヘルス センター 癌及び感染性疾患の治療に有用な熱ショックタンパク質又はα−２−マクログロブリンを含む組成物の調製方法
WO2003070909A2 (en) 2002-02-20 2003-08-28 Chiron Corporation Microparticles with adsorbed polypeptide-containing molecules
EP1547607A4 (de) * 2002-08-02 2008-11-26 Dainippon Sumitomo Pharma Co Herstellung einer komponente des bakterienzellwand-skeletts
GB0220194D0 (en) 2002-08-30 2002-10-09 Chiron Spa Improved vesicles
BR0315767A (pt) 2002-11-01 2005-09-06 Glaxosmithkline Biolog Sa Composição imunogência, método para fabricar uma vacina, kit, vacina, recipiente com uma superfìcie interna repelente à água, e, método para preservar uma composição que compreende ipv e um agente estabilizador
PT2279746E (pt) 2002-11-15 2013-12-09 Novartis Vaccines & Diagnostic Proteínas de superfície de neisseria meningitidis
GB0227346D0 (en) 2002-11-22 2002-12-31 Chiron Spa 741
WO2004060396A2 (en) 2002-12-27 2004-07-22 Chiron Corporation Immunogenic compositions containing phospholpid
US7893096B2 (en) 2003-03-28 2011-02-22 Novartis Vaccines And Diagnostics, Inc. Use of small molecule compounds for immunopotentiation
GB0308198D0 (en) 2003-04-09 2003-05-14 Chiron Srl ADP-ribosylating bacterial toxin
US7731967B2 (en) 2003-04-30 2010-06-08 Novartis Vaccines And Diagnostics, Inc. Compositions for inducing immune responses
ES2596553T3 (es) 2003-06-02 2017-01-10 Glaxosmithkline Biologicals Sa Composiciones inmunogénicas a base de micropartículas que comprenden toxoide adsorbido y un antígeno que contiene un polisacárido
EP1654283B1 (de) 2003-08-13 2011-07-13 Novartis Vaccines and Diagnostics, Inc. Verbessertes verfahren zur reinigung von tfpi und tfpi-analogen
WO2005080414A1 (en) 2004-02-19 2005-09-01 Ramot At Tel-Aviv University Ltd Peptide mimotopes of mycobacterial mannosylated lipoglycans and uses thereof
WO2005102369A1 (ja) * 2004-04-22 2005-11-03 Dainippon Sumitomo Pharma Co., Ltd. 細菌細胞壁骨格成分を含有する製剤
CA2571421A1 (en) 2004-06-24 2006-01-05 Nicholas Valiante Compounds for immunopotentiation
EP1768662A2 (de) 2004-06-24 2007-04-04 Novartis Vaccines and Diagnostics, Inc. Immunstimulatoren kleiner moleküle und assays für deren nachweis
DE602005017391D1 (de) 2004-06-24 2009-12-10 Yissum Res Dev Co Verwendung von peptid-mimotopen von mannosylierten lipoglycanen aus mycobacterien zur behandlung von entzündungen
JP2008508320A (ja) 2004-07-29 2008-03-21 カイロン コーポレイション Ｓｔｒｅｐｔｏｃｏｃｃｕｓａｇａｌａｃｔｉａｅのようなグラム陽性細菌に対する免疫原性組成物
EP1838340B1 (de) * 2004-12-22 2018-04-04 Cleveland Clinic Foundation Mit flagellin verwandte polypeptide und ihre verwendungen
WO2007047749A1 (en) 2005-10-18 2007-04-26 Novartis Vaccines And Diagnostics Inc. Mucosal and systemic immunizations with alphavirus replicon particles
WO2007081447A2 (en) 2005-11-22 2007-07-19 Novartis Vaccines And Diagnostics, Inc. Norovirus and sapovirus antigens
CA2646539A1 (en) 2006-03-23 2007-09-27 Novartis Ag Imidazoquinoxaline compounds as immunomodulators
KR100846494B1 (ko) * 2006-09-26 2008-07-17 삼성전자주식회사 헬리코박터 파일로리의 표적 서열을 증폭하기 위한프라이머 세트, 상기 프라이머 세트를 이용하여 헬리코박터파일로리를 검출하는 방법 및 상기 프라이머 세트를포함하는 헬리코박터 파일로리를 검출하는 키트
GB0700562D0 (en) 2007-01-11 2007-02-21 Novartis Vaccines & Diagnostic Modified Saccharides
ES2561483T3 (es) 2007-09-12 2016-02-26 Glaxosmithkline Biologicals Sa Antígenos mutantes de GAS57 y anticuerpos de GAS57
KR101773114B1 (ko) 2007-12-21 2017-08-30 노파르티스 아게 스트렙토라이신 ｏ의 돌연변이 형태
JP5577337B2 (ja) 2008-08-01 2014-08-20 クリーブランド バイオラブス， インコーポレイテッド 再灌流傷害を治療するための方法
EP2331127A2 (de) 2008-09-18 2011-06-15 Novartis AG Vakzine-adjuvans-kombinationen
US8465751B2 (en) 2009-01-12 2013-06-18 Novartis Ag Cna—B domain antigens in vaccines against gram positive bacteria
AU2010288239B2 (en) 2009-08-27 2014-01-16 Novartis Ag Adjuvant comprising aluminium, oligonucleotide and polycation
MX2012002723A (es) 2009-09-02 2012-04-11 Novartis Ag Composiciones inmunogenicas que incluyen moduladores de la actividad de receptores tipo toll.
KR20130121699A (ko) 2010-05-28 2013-11-06 테트리스 온라인, 인코포레이티드 상호작용 혼성 비동기 컴퓨터 게임 기반구조
ES2458355T3 (es) 2010-09-01 2014-05-05 Novartis Ag Adsorción de inmunopotenciadores sobre sales metálicas insolubles
WO2012082914A1 (en) 2010-12-14 2012-06-21 Novartis Ag Flow cytometry analysis of materials adsorbed to metal salts
AU2012205681B2 (en) 2011-01-10 2016-07-28 Cleveland Biolabs, Inc. Use of toll-like receptor agonist for treating cancer
RU2013144207A (ru) 2011-03-02 2015-04-10 Новартис Аг Комбинированные вакцины с пониженными дозами антигена и/или адъюванта
WO2013131983A1 (en) 2012-03-07 2013-09-12 Novartis Ag Adjuvanted formulations of streptococcus pneumoniae antigens
DK2822947T3 (en) 2012-03-07 2016-09-19 Glaxosmithkline Biologicals Sa ARGINAL SALTS OF A TLR-7 AGONIST
RU2014140521A (ru) 2012-03-08 2016-04-27 Новартис Аг Адъювантные составы бустерных вакцин
EP2877852B1 (de) * 2012-07-23 2022-05-25 Hermouet, Sylvie Protein-mikroarray zur charakterisierung der spezifität der monoklonalen immunoglobuline von mgus- oder myelom-patienten
AU2015296555B2 (en) 2014-07-30 2020-05-21 Genome Protection, Inc. Flagellin compositons and uses
US10183056B2 (en) 2014-10-16 2019-01-22 Cleveland Biolabs, Inc. Methods and compositions for the treatment of radiation-related disorders
SE541618C2 (en) * 2017-02-24 2019-11-12 Biotome Pty Ltd Novel peptides and their use in diagnosis

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0274482B2 (de) 1986-03-28 2003-03-12 The Board Of Trustees Of The University Of Illinois Mit mehrfacharzneimittelresistenz assoziierte,isolierte dna-sequenzen in menschlichen zellen
US5554372A (en) 1986-09-22 1996-09-10 Emory University Methods and vaccines comprising surface-active copolymers
US5459041A (en) * 1988-02-18 1995-10-17 Enteric Research Laboratories, Inc. Campylobacter pylori antigens and uses thereof for detection of Campylobacter pylori infection
US4882271A (en) * 1988-03-10 1989-11-21 Baylor College Of Medicine Process for preparation of high molecular weight cell-associated protein of campylobacter pylori and use for serological detection of campylobacter pylori infection
FR2637612B1 (fr) * 1988-10-06 1993-09-10 Pasteur Institut Sequences de nucleotides codant pour une proteine a activite ureasique
JP3436756B2 (ja) 1988-12-19 2003-08-18 アメリカン・サイアナミド・カンパニー 髄膜炎菌のクラスｉの外膜タンパク質のワクチン
GB8928625D0 (en) * 1989-12-19 1990-02-21 3I Res Expl Ltd H.pylori dna probes
US5292658A (en) 1989-12-29 1994-03-08 University Of Georgia Research Foundation, Inc. Boyd Graduate Studies Research Center Cloning and expressions of Renilla luciferase
ATE241704T1 (de) 1991-08-27 2003-06-15 Hoffmann La Roche Primers und sondern zum nachweis von hepatitis c
US5354854A (en) 1991-11-07 1994-10-11 The Curators Of The University Of Missouri Expression system for use in plants to suppress foreign expression and method
US5721349A (en) * 1992-02-26 1998-02-24 Vanderbilt University Vacuolating toxin-deficient H. pylori
IT1262895B (it) 1992-03-02 1996-07-22 Proteina estratta da ceppi citotossici di helicobacter pylori, gene che la esprime, uso della proteina come vaccino o diagnostico.
US5403924A (en) * 1992-10-13 1995-04-04 Vanderbilt University Taga gene and methods for detecting predisposition to peptic ulceration
US5733740A (en) 1992-10-13 1998-03-31 Vanderbilt University Taga gene and methods for detecting predisposition to peptic ulceration and gastric carcinoma
US6019982A (en) * 1994-08-26 2000-02-01 The Administrators Of The Tulane Educational Fund Mutant enterotoxin effective as a non-toxic oral adjuvant
US6902903B1 (en) 1996-12-19 2005-06-07 Chiron Corporation Helicobacter pylori diagnostics
CA2408328C (en) 2000-05-10 2012-04-17 Aventis Pasteur Limited Immunogenic polypeptides encoded by mage minigenes and uses thereof

Also Published As

Publication number Publication date
JP2006055168A (ja) 2006-03-02
EP0967279A1 (de) 1999-12-29
DE69333110T2 (de) 2004-05-06
CA2131729A1 (en) 1993-09-16
EP0967279B1 (de) 2008-01-02
JP3368902B2 (ja) 2003-01-20
JP2000350591A (ja) 2000-12-19
CA2131729C (en) 2008-02-12
CA2383007A1 (en) 1993-09-16
WO1993018150A1 (en) 1993-09-16
DE69333110D1 (de) 2003-08-28
JP2000333686A (ja) 2000-12-05
AU3630093A (en) 1993-10-05
US20040048353A1 (en) 2004-03-11
DE69334197T2 (de) 2008-12-11
US7700755B2 (en) 2010-04-20
US6077706A (en) 2000-06-20
US20050276819A1 (en) 2005-12-15
JPH07504565A (ja) 1995-05-25
JP3408494B2 (ja) 2003-05-19

Similar Documents

Publication Publication Date Title
DE69334197D1 (de) Helicobacter pylori Cytotoxin verwendbar in Impfstoffe und Diagnostik
DE69128981D1 (de) Geheimübertragungsverfahren und Geheimübertragungseinrichtung
DE69315950T2 (de) Aufzeichnungsgerät und Aufzeichnungsverfahren
NO975490L (no) Heliobacter pylori antigener og vaksinesammensetninger
DE69222259T2 (de) Bilderzeugungsgerät und -verfahren
KR890016831A (ko) 화상확대방법 및 장치
DE68928726T2 (de) Bilderausrichtungsverfahren und -gerät
DE69034055D1 (de) Bilderzeugungsgerät und Modulationsverfahren
DE69124571D1 (de) Emulgierverfahren und -vorrichtung
NO894442D0 (no) Anordning og fremgangsmaate for tetting av eske-emner.
DE69325151D1 (de) Datenaufnahmeverfahren und Datenaufnahmegerät
DE68913903D1 (de) Übertragungsvorrichtung und Bilderzeugungsgerät in einem.
DE68926386D1 (de) Bildkodiervorrichtung und Bildkodierverfahren
DE69123660D1 (de) Datenkompressionsmethode und Gerät
DE69029534D1 (de) Aufzeichnungseinrichtung und Aufzeichnungsmethode
DE69125315D1 (de) Kodierverfahren und Kodiervorrichtung
DE69407483T2 (de) Aufzeichnungsgerät und Aufzeichnungsverfahren
DE69101974T2 (de) Gerät zum Mischen und Granulieren.
DE68904814D1 (de) Bilderzeugungsvorrichtung und bilderzeugungsverfahren.
DE69425770D1 (de) Direktes Aufzeichnungsverfahren und direkte Aufzeichnungsvorrichtung
DE69315404T2 (de) Aufzeichnungsgerät und Aufzeichnungsverfahren
DE69419065T2 (de) Bildtransformationsvorrichtung und -verfahren
DE69019922T2 (de) Thermokopf und Thermoübertragungsvorrichtung.
DE69001135T2 (de) Loetverfahren und loetgeraet.
DE69124565T2 (de) Gassyntheseverfahren und -vorrichtung

Legal Events

Date Code Title Description
8364 No opposition during term of opposition